In recent trading session, Coherus Biosciences Inc (NASDAQ:CHRS) saw 0.54 million shares changing hands at last check today with its beta currently measuring 0.67. Company’s recent per share price level of $2.27 trading at $0.1 or 4.49% at last check today assigns it a market valuation of $257.36M. That most recent trading price of CHRS’s stock is at a discount of -262.11% from its 52-week high price of $8.22 and is indicating a premium of 37.0% from its 52-week low price of $1.43. Taking a look at company’s average trading volume of 2.44 million if we extend that period to 3-months.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Upright in the green today for gaining 4.49%, in the last five days CHRS remained trading in the green while hitting it’s week-highest on Friday, 05/03/24 when the stock touched $2.27 price level, adding 2.16% to its value on the day. Coherus Biosciences Inc’s shares saw a change of -31.91% in year-to-date performance and have moved 11.15% in past 5-day. Coherus Biosciences Inc (NASDAQ:CHRS) showed a performance of -2.68% in past 30-days.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Statistics highlight that Coherus Biosciences Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -29.14% of value to its shares in past 6 months, showing an annual growth rate of 100.51% while that of industry is 12.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 9.00% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 80.25M for the same. And 5 analysts are in estimates of company making revenue of 53.68M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 4.73% during past 5 years.
CHRS Dividends
Coherus Biosciences Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
